Shattuck Labs, Inc. Common Stock STTK
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $14.88 (+139.9% upside)
Key Stats
- Today's Range
- $6.08 – $6.26
- 50-Day Range
- $6.06 – $8.15
- 52-Week Range
- $0.71 – $8.33
- Volume
- 822K shs
- Average Volume
- 868K shs
- Market Cap
- $622.25 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.95
- Price / Sales
- 622.25
Short Interest
- Short Interest
- 0.64%
- Days to Cover
- 1.29
Financials (TTM)
- Revenue
- $1.00 million
- Net Income
- $-52,568,000
- Net Margin
- -5256.80%
- Return on Equity
- -24.90%
- Debt-to-Equity
- —
About Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Related Stocks
Compare head-to-head: STTK vs LLY·STTK vs JNJ·STTK vs ABBV·STTK vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.